Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

HRMY – Harmony Biosciences Holdings, Inc.

Float Short %

9.67

Margin Of Safety %

26

Put/Call OI Ratio

0.33

EPS Next Q Diff

0.37

EPS Last/This Y

1.4

EPS This/Next Y

1.39

Price

37.87

Target Price

50.55

Analyst Recom

1.45

Performance Q

10.93

Relative Volume

0.81

Beta

0.84

Ticker: HRMY




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25HRMY37.550.260.014487
2025-07-28HRMY35.770.140.228051
2025-07-29HRMY35.450.140.928227
2025-07-30HRMY35.50.140.258265
2025-07-31HRMY35.060.140.918308
2025-08-01HRMY34.380.140.038318
2025-08-04HRMY35.550.1446.138335
2025-08-05HRMY35.010.420.0410415
2025-08-06HRMY34.690.330.0912638
2025-08-07HRMY34.210.340.4912572
2025-08-08HRMY34.210.340.7012690
2025-08-11HRMY34.830.350.3012804
2025-08-12HRMY35.480.350.4512795
2025-08-13HRMY36.710.362.9312951
2025-08-14HRMY36.50.360.5413023
2025-08-15HRMY36.880.360.8113062
2025-08-18HRMY36.430.200.124672
2025-08-19HRMY36.390.180.116207
2025-08-20HRMY36.630.170.007374
2025-08-21HRMY37.420.1710.477486
2025-08-22HRMY37.90.332.438670
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25HRMY37.52-0.798.44.15
2025-07-28HRMY35.87-0.774.64.15
2025-07-29HRMY35.45-0.787.24.15
2025-07-30HRMY35.48-0.790.64.15
2025-07-31HRMY35.18-0.787.34.15
2025-08-01HRMY34.40-9.082.24.06
2025-08-04HRMY35.54-9.0102.64.06
2025-08-05HRMY34.94-9.084.24.06
2025-08-06HRMY34.682.087.74.06
2025-08-07HRMY34.192.057.94.06
2025-08-08HRMY34.19-3.750.13.94
2025-08-11HRMY34.83-3.757.73.94
2025-08-12HRMY35.48-2.857.93.96
2025-08-13HRMY36.67-2.862.93.96
2025-08-14HRMY36.49-2.848.93.96
2025-08-15HRMY36.87-2.854.33.96
2025-08-18HRMY36.45-2.846.73.96
2025-08-19HRMY36.40-2.850.63.96
2025-08-20HRMY36.63-2.853.13.96
2025-08-21HRMY37.28-2.857.13.96
2025-08-22HRMY37.87-2.856.33.96
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25HRMY-0.21-4.9210.20
2025-07-28HRMY-0.21-4.7610.20
2025-07-29HRMY-0.09-4.7610.20
2025-07-30HRMY-0.09-4.7610.20
2025-07-31HRMY-0.09-4.7610.20
2025-08-01HRMY-0.09-4.7610.20
2025-08-04HRMY-0.09-5.4710.20
2025-08-05HRMY-0.09-5.4710.20
2025-08-06HRMY-0.09-5.4710.20
2025-08-07HRMY-0.09-5.4710.20
2025-08-08HRMY-0.09-5.4710.18
2025-08-11HRMY-0.09-5.4210.18
2025-08-12HRMY-0.09-5.429.67
2025-08-13HRMY-0.09-5.429.67
2025-08-14HRMY-0.09-5.429.67
2025-08-15HRMY-0.09-5.429.67
2025-08-18HRMY-0.09-4.099.67
2025-08-19HRMY-0.24-4.099.67
2025-08-20HRMY-0.24-4.099.67
2025-08-21HRMY-0.24-4.099.67
2025-08-22HRMY-0.24-4.099.67
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.68

Avg. EPS Est. Current Quarter

1

Avg. EPS Est. Next Quarter

1.05

Insider Transactions

-0.24

Institutional Transactions

-4.09

Beta

0.84

Average Sales Estimate Current Quarter

220

Average Sales Estimate Next Quarter

235

Fair Value

47.65

Quality Score

98

Growth Score

95

Sentiment Score

64

Actual DrawDown %

39

Max Drawdown 5-Year %

-68.5

Target Price

50.55

P/E

12.2

Forward P/E

9.73

PEG

0.53

P/S

2.82

P/B

2.82

P/Free Cash Flow

8.42

EPS

3.1

Average EPS Est. Cur. Y​

3.96

EPS Next Y. (Est.)

5.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

23.42

Relative Volume

0.81

Return on Equity vs Sector %

-1.3

Return on Equity vs Industry %

11.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.19

EBIT Estimation

56.3
Harmony Biosciences Holdings, I
Sector: Healthcare
Industry: Biotechnology
Employees: 268
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
stock quote shares HRMY – Harmony Biosciences Holdings, Inc. Stock Price stock today
news today HRMY – Harmony Biosciences Holdings, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch HRMY – Harmony Biosciences Holdings, Inc. yahoo finance google finance
stock history HRMY – Harmony Biosciences Holdings, Inc. invest stock market
stock prices HRMY premarket after hours
ticker HRMY fair value insiders trading